We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
-1.36%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.32B
AUM Growth
-$280M
(-18%)
Cap. Flow
-$198M
Cap. Flow
% of AUM
-15.04%
Top 10 Holdings %
Top 10 Hldgs %
17.04%
Holding
1,626
New
448
Increased
346
Reduced
313
Closed
483
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$9.86M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$9.7M |
| 3 |
CNR
Core Natural Resources Inc
CNR
|
+$8.26M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$6.63M |
| 5 |
Oracle
ORCL
|
+$6.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SMAR
Smartsheet Inc.
SMAR
|
+$14M |
| 2 |
HTLF
Heartland Financial USA, Inc.
HTLF
|
+$11.1M |
| 3 |
NVIDIA
NVDA
|
+$9.36M |
| 4 |
Amazon
AMZN
|
+$8.75M |
| 5 |
Netflix
NFLX
|
+$8.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.2% |
| 2 | Healthcare | 10.48% |
| 3 | Consumer Discretionary | 9.93% |
| 4 | Financials | 7.26% |
| 5 | Communication Services | 6.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NFGC
1101
New Found Gold
NFGC
$653M
| $41.6K | ﹤0.01% |
+34,662
| New | +$59.8K |
|
1102
Amplify Energy
AMPY
$172M
| $41.2K | ﹤0.01% |
11,007
-21,702
| -66% | -$108K |
|
1103
Cineverse
CNVS
$66M
| $41.1K | ﹤0.01% |
+13,000
| New | +$48.7K |
|
1104
Smart Sand
SND
$197M
| $38.6K | ﹤0.01% |
+14,900
| New | +$35K |
|
1105
DocGo
DCGO
$56.8M
| $38.5K | ﹤0.01% |
+14,600
| New | +$58.6K |
|
1106
CALL
Sabre
SABR
$835M
| $37.1K | ﹤0.01% |
+13,200
| New | +$46.7K |
|
1107
Metagenomi Therapeutics
MGX
$46.3M
| $34.8K | ﹤0.01% |
25,556
-10,486
| -29% | -$25K |
|
|
TE
1108
T1 Energy
TE
$1.48B
| $34.4K | ﹤0.01% |
+27,266
| New | +$50.3K |
|
|
MAPS
1109
DELISTED
WM TECHNOLOGY INC A
MAPS
| $34.3K | ﹤0.01% |
+30,310
| New | +$40.4K |
|
1110
Denison Mines
DNN
$2.95B
| $33.8K | ﹤0.01% |
26,038
-101,727
| -80% | -$170K |
|
1111
Sundial Growers
SNDL
$303M
| $33.6K | ﹤0.01% |
23,865
-1,053,625
| -98% | -$1.79M |
|
|
HLVX
1112
DELISTED
HilleVax
HLVX
| $32K | ﹤0.01% |
22,100
+5,800
| +36% | +$10.7K |
|
1113
Corvus Pharmaceuticals
CRVS
$1.16B
| $31.9K | ﹤0.01% |
+10,027
| New | +$47.2K |
|
1114
Lantronix
LTRX
$256M
| $31.5K | ﹤0.01% |
12,666
-8,000
| -39% | -$25.8K |
|
1115
United States Antimony
UAMY
$988M
| $31.5K | ﹤0.01% |
+14,300
| New | +$24.8K |
|
1116
AtaiBeckley Inc
ATAI
$2.68B
| $30.3K | ﹤0.01% |
22,308
-13,033
| -37% | -$21.9K |
|
1117
Vera Bradley
VRA
$96.4M
| $29.8K | ﹤0.01% |
13,243
-7,857
| -37% | -$25.4K |
|
1118
Zentalis Pharmaceuticals
ZNTL
$297M
| $29.7K | ﹤0.01% |
18,710
-800
| -4% | -$1.73K |
|
1119
Alto Neuroscience
ANRO
$1.1B
| $29.5K | ﹤0.01% |
13,645
+1,400
| +11% | +$5.01K |
|
1120
Oramed Pharmaceuticals
ORMP
$175M
| $28.8K | ﹤0.01% |
13,435
-300
| -2% | -$692 |
|
1121
Acrivon Therapeutics
ACRV
$74.5M
| $26.5K | ﹤0.01% |
+13,067
| New | +$70.3K |
|
1122
Adicet Bio
ACET
$75.9M
| $25.9K | ﹤0.01% |
2,140
+333
| +18% | +$4.76K |
|
1123
indie Semiconductor
INDI
$786M
| $25.2K | ﹤0.01% |
12,399
-4,051
| -25% | -$14.1K |
|
1124
Comstock
LODE
$247M
| $25.2K | ﹤0.01% |
+10,316
| New | +$34.3K |
|
|
BOLD
1125
Boundless Bio
BOLD
$64.1M
| $25.1K | ﹤0.01% |
16,624
| – | – |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Prelude Capital Management held 1,626 positions worth $1.32B, down 18% from $1.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Prelude Capital Management withdrew a net $198M in Q1 2025, closing 483 positions and reducing 313 holdings. Its most notable exit was Smartsheet Inc., an estimated $14M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Prelude Capital Management opened a new position in Intra-Cellular Therapies Inc. worth $10.4M.
- Prelude Capital Management's largest Q1 2025 buy was Intra-Cellular Therapies Inc.: 79,142 shares worth $10.4M.
- Prelude Capital Management added most to Alphabet (Google) Class A in Q1 2025, an estimated $9.7M increase.
- Prelude Capital Management's biggest Q1 2025 reduction was NVIDIA, cutting an estimated $9.36M.
- Prelude Capital Management fully exited Smartsheet Inc. in Q1 2025, selling an estimated $14M.
- Prelude Capital Management's ten largest holdings make up 17% of its $1.32B portfolio in Q1 2025.
- Prelude Capital Management opened 448 new positions and closed 483 in Q1 2025.
- Prelude Capital Management's portfolio value fell 18% quarter-over-quarter to $1.32B.
Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.